MYCN, a member of the MYC family of oncogenes, encodes a nuclear protein functioning as a transcription factor. It binds active promoters in a heterodimer with MAX and is involved in RNA metabolism as it interacts with the nuclear exosome [1]. MYCN controls multiple aspects of cell fate such as cellular proliferation, differentiation, apoptosis, and cellular metabolism [5]. It has a restricted spatiotemporal expression predominantly in neural crest cells, which is associated with neoplasms like neuroblastoma and central nervous system tumours [5].

In neuroblastoma, MYCN amplification, seen in about 25% of cases, is strongly correlated with high-risk disease and poor prognosis [3,4,5]. In MYCN-amplified neuroblastoma cells, targeting the 5' untranslated region (UTR) of MYCN using an amidino-rocaglate to inhibit eIF4A1 activity led to growth inhibition without generalized toxicity, highlighting the therapeutic potential of this approach [2]. Also, MYCN drives oncogenesis in neuroblastoma by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to regulate global gene transcription. Targeting both WDR5 and G9a inhibitors synergistically suppresses NB growth [6].

In conclusion, MYCN is a crucial regulator in cell fate-related processes. Its amplification in neuroblastoma is a significant prognostic factor. Studies in neuroblastoma models have provided insights into potential therapeutic strategies targeting MYCN-associated pathways, offering hope for improving patient outcomes in this high-risk disease.